Predictive Factors of Restenosis After Coronary Stent Placement  by Kastrati, Adnan et al.
Predictive Factors of Restenosis After Coronary Stent Placement
ADNAN KASTRATI, MD, ALBERT SCHO¨MIG, MD, SHPEND ELEZI, MD,
HELMUT SCHU¨HLEN, MD, JOSEF DIRSCHINGER, MD, MARTIN HADAMITZKY, MD,
ANNE WEHINGER, MD, JO¨RG HAUSLEITER, MD, HANNA WALTER, MD,
FRANZ-JOSEF NEUMANN, MD
Munich, Germany
Objectives. The objective of this study was to identify clinical,
lesional and procedural factors that can predict restenosis after
coronary stent placement.
Background. Coronary stent placement reduces the restenosis
rate compared with that after percutaneous transluminal coro-
nary angioplasty (PTCA). However, restenosis remains an unre-
solved issue, and identification of its predictive factors may allow
further insight into the underlying process.
Methods. All patients with successful coronary stent placement
were eligible for this study unless they had had a major adverse
cardiac event during the 1st 30 days after the procedure. Of the
1,349 eligible patients (1,753 lesions), follow-up angiography at 6
months was performed in 80.4% (1,084 patients, 1,399 lesions).
Demographic, clinical, lesional and procedural data were prospec-
tively recorded and analyzed for any predictive power for the
occurrence of late restenosis after stenting. Restenosis was eval-
uated by using three outcomes at follow-up: binary restenosis as a
diameter stenosis >250%, late lumen loss as lumen diameter
reduction and target lesion revascularization (TLR) as any repeat
PTCA or coronary artery bypass surgery involving the stented
lesion.
Results. Multivariate analysis demonstrated that diabetes mel-
litus, placement of multiple stents and minimal lumen diameter
(MLD) immediately after stenting were the strongest predictors of
restenosis. Diabetes increased the risk of binary restenosis with
an odds ratio (OR) [95% confidence interval] of 1.86 [1.56 to 2.16]
and the risk of TLR with an OR of 1.45 [1.11 to 1.80]. Multiple
stents increased the risk of binary restenosis with an OR of 1.81
[1.55 to 2.06] and that of TLR with an OR of 1.94 [1.66 to 2.22].
An MLD <3 mm at the end of the procedure augmented the risk
of binary restenosis with an OR of 1.81 [1.55 to 2.06] and that of
TLR with an OR of 2.05 [1.77 to 2.34]. Classification and
regression tree analysis demonstrated that the incidence of re-
stenosis may be as low as 16% for a lesion without any of these risk
factors and as high as 59% for a lesion with a combination of these
risk factors.
Conclusions. Diabetes, multiple stents and smaller final MLD
are strong predictors of restenosis after coronary stent placement.
Achieving an optimal result with a minimal number of stents
during the procedure may significantly reduce this risk even in
patients with adverse clinical characteristics such as diabetes.
(J Am Coll Cardiol 1997;30:1428–36)
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Coronary stent placement is increasingly used to improve the
early outcome (1,2) and reduce late restenosis after percuta-
neous transluminal coronary angioplasty (PTCA) (3,4). The
problem of early stent occlusion has been minimized by a
better antithrombotic regimen after PTCA (5). The Intracoro-
nary Stenting and Antithrombotic Regimen (ISAR) trial has
shown that this strategy is particularly effective in high risk
patients (6); hence, the broadening of indications for stent
placement is now well justified. However, even a restenosis
rate of 20% to 30% after stenting (3,4,7), often achieved in
rather selected lesions (3,4), continues to impose a relevant
limitation to the management of patients with coronary artery
disease. The pathogenesis of restenosis is not completely
understood (8), and identifying predictive factors may allow
some insight into this complex process. Numerous studies have
examined the role of various clinical, angiographic and proce-
dural factors in predicting restenosis after PTCA. However,
specific aspects of stent placement technique as well as of
stent-induced vascular injury and repair may not justify extrap-
olation of these findings to patients after coronary stent
implantation. Intravascular ultrasound studies suggested that
neointimal hyperplasia might be the sole mechanism respon-
sible for restenosis after stenting (9), in contrast to conven-
tional coronary angioplasty where arterial remodeling has a
predominant role in late lumen renarrowing (10). Further-
more, knowledge of risk factors for restenosis after coronary
stent placement may help to optimize indications and stent
deployment technique and to guide strategies against this
vexing problem. The objective of the present study was to
identify clinical, lesional and procedural factors able to predict
restenosis after coronary stenting.
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Methods
Patients. Stenting was attempted in 1,494 patients at our
institution during the period from May 1992 through April
1996. Indications for stenting were extensive coronary artery
dissections or suboptimal results (residual stenosis .30%)
after PTCA and lesions in venous bypass grafts. We excluded
from this study patients with coronary stent implantation in the
setting of cardiogenic shock complicating acute myocardial
infarction (37 patients, 2.5%); patients with unsuccessful stent-
ing, defined as failure to place the stent at the desired site or
to achieve a satisfactory angiographic result (i.e., residual
stenosis ,30%) (41 patients, 2.7%); patients with stenting
intended primarily as a bridge to coronary artery bypass graft
surgery (CABG) (11 patients, 0.7%); patients with any major
adverse cardiac event during the 1st 30 days after the proce-
dure such as death, myocardial infarction, CABG, repeat
PTCA or stent vessel occlusion (56 patients, 3.7%). Thus, 1,349
patients with successful stent placement in 1,753 coronary
lesions were eligible for this study. All were asked to undergo
control angiography and clinical follow-up at 6 months (or
earlier in case of symptoms or objective signs of ischemia). If
the angiographic control study had taken place before the
preset time and had not resulted in a reintervention at the
target lesion, the patients were encouraged to undergo repeat
angiography. Follow-up angiography at a median of 188 days
(interquartile range 173 to 203 days) was carried out in 1,084
patients (80.4%), representing 1,399 lesions for analysis.
Stent placement and post-stenting treatment. The stent
implantation technique has been described previously (2). All
patients received heparin (15,000 U) and aspirin (500 mg)
intravenously before PTCA. Short 7-mm or articulated 15-mm
Palmaz-Schatz stents (Johnson & Johnson) were delivered
under fluoroscopic guidance after having been hand-crimped
on conventional angioplasty balloons. In all cases conventional
balloon angioplasty was the only procedure performed before
stent placement. Balloon size and pressure were at the oper-
ator’s discretion. Multiple stents were deployed if necessary to
cover the full extent of the target lesion or the dissection if it
occurred. Adequacy of the final result was based solely on the
angiographic assessment; intravascular ultrasound was used in
,10% of cases.
After sheath removal and application of a pressure ban-
dage, heparin infusion was started in all patients and continued
for 12 h. All patients were given aspirin (100 mg orally twice
daily) throughout the study. Subsequent therapy depended on
the treatment strategy selected, reflecting the overall changing
attitude in this respect. In the 1st 2 years of this study patients
were treated with an anticoagulation regimen comprising
heparin for 5 to 10 days and phenprocoumon (Marcumar,
Hoffmann-La Roche, Grenzach-Wyhlen, Germany) for 4 to 6
weeks, whereas most patients in the last 2 years were treated
with combined antiplatelet therapy with ticlopidine (250 mg
twice daily) in addition to aspirin.
Coronary angiographic evaluation. Qualitative angio-
graphic assessment was done by the operator during or imme-
diately after the procedure. The angiogram was assessed for
the presence of vessel occlusion before PTCA or stenting and
dissections (11) immediately before stent placement. The
vessel was considered occluded in the presence of Thrombol-
ysis in Myocardial Infarction (TIMI) flow grade 0 or 1. The
occlusion was considered recent in the setting of acute myo-
cardial infarction or if it occurred as a complication of the
PTCA procedure preceding stent implantation; otherwise it
was considered chronic.
Quantitative angiographic analysis was made by operators
not involved in the intervention who used the automated edge
detection system CMS (Medis Medical Imaging Systems,
Nuenen, The Netherlands). The contrast-filled nontapered
catheter tip was used for calibration. Minimal lumen diameter
(MLD), reference diameter (RD), percent diameter stenosis
as well as the diameter of the maximally inflated balloon were
obtained from this analysis system. The measurements were
done for the angiogram before and immediately after stenting,
and for that recorded at follow-up. Balloon/vessel ratio was
calculated as diameter of the inflated balloon divided by the
coronary RD. Late loss was computed as the difference
between the final post-stenting MLD and the MLD found at
follow-up angiography.
Risk factors analyzed and study end points. All demo-
graphic, clinical, angiographic and procedural characteristics
were recorded prospectively. They were selected as potential
risk factors for restenosis on the basis of earlier experience
with PTCA. Age, gender, the presence of hypercholesterol-
emia, systemic arterial hypertension, smoking, diabetes melli-
tus, acute myocardial infarction, unstable angina pectoris,
multivessel disease, previous PTCA, recent occlusion, chronic
occlusion and dissection, as well as vessel stented, RD and
MLD before stenting, maximal balloon pressure, balloon/
vessel ratio and MLD immediately after stenting were vari-
ables included in the list. It had previously been shown (12,13)
that lesions in the left anterior descending coronary artery
(LAD) have a higher risk of restenosis. Therefore, the target
vessel was simplified here by distinguishing LAD and non-
LAD. In addition, a specific factor for stenting, the number of
stents implanted, was included. Because of the frequent use of
short (7-mm) stents, the 7-mm stent was used as the unit of
measure of this variable. Therefore, a standard articulated
Palmaz-Schatz stent was counted as two stent units. Multiple
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CART 5 classification and regression tree
ISAR 5 Intracoronary Stenting and Antithrombotic Regimen
trial
LAD 5 left anterior descending coronary artery
MLD 5 minimal lumen diameter
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
RD 5 reference diameter
TLR 5 target lesion revascularization
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stents was defined as the placement of more than two stent
units. Although the ISAR study did not show any difference in
restenosis rate between the two treatment strategies, anticoag-
ulant or antiplatelet agents, we entered the type of post-
stenting therapy into the list of risk factors, because of the
much greater number of patients studied here.
The end points of the study were three different measures
of lesion restenosis at 6 months: binary restenosis defined as a
$50% diameter stenosis at follow-up, late lumen loss as
defined above and target lesion revascularization (TLR) as a
binary variable. TLR was defined as repeat PTCA or CABG
involving the stented lesion, driven by clinical signs of ischemia
in the presence of angiographic restenosis. We used these
three measures of restenosis to correct for the weaknesses
presented by each of them alone.
Data analysis. Possible differences in the risk factor profile
for restenosis between the groups with and without follow-up
angiography were checked by means of the t test for indepen-
dent samples (two-sided test) for continuous data and chi-
square test for discrete data. To control for the errors pro-
duced by possible deviations of the continuous variables from
a normal distribution, this analysis was validated by using
nonparametric methods such as the Mann-Whitney test, which
yielded similar results.
The main analysis tested the association of any risk factor
with a worse outcome at follow-up in terms of the three end
points of this study. We chose to make an analysis on a per
lesion basis because there is convincing evidence (14,15) for a
lesion dependence of restenosis. However, we checked the
validity of this approach by repeating the most important
analyses on a per patient basis as well. All continuous variables
were first transformed to binary data with 1 for the presence of
the assumed risk factor and 0 otherwise. We used the median
of each variable as the cutoff point for this division, avoiding
the use of any other arbitrary value.
We used three methods of analysis. 1) The risk each factor
presents for the three end points of the study was estimated by
means of univariate analysis, performing chi-square tests and
calculating the relative risk in the case of binary restenosis and
TLR and t test for independent samples (two-sided) for late
lumen loss. 2) Multivariate stepwise logistic regression analysis
was carried out to identify independent correlates of restenosis
and TLR. All potential risk factors were part of the model. We
did not preselect independent variables to enter into the model
in order to avoid a bias by arbitrarily canceling possible
independent or interaction effects of some variables. The
significant risk factors are presented with their respective odds
ratio (OR) calculated by the logistic regression program (SPSS
version 7.0, SPSS Inc.). Stepwise multiple linear regression was
used for late lumen loss; the results presented consist of the
regression coefficients for the significant correlates. 3) We used
a tree-based modeling technique of predictive factors for
restenosis and TLR rates. This was done by constructing
classification and regression trees (CART) for both binary
outcomes (S-Plus version 3.3, StaSci Division, MathSoft, Inc.).
This method with its flow chart–like graphic presentation helps
in a simple and very demonstrative way to predict the outcome
of patients in the presence of one or more risk factors before
a decision is made on the treatment strategy. A disadvantage of
this method is that it does not take into account a possible
interplay of the risk factors entered into the model. For this
reason we constructed the CART using only the independent
correlates of the outcome as determined by logistic regression
analysis. Only the first four divisions of the tree were retained,
because the tree becomes less stable with more levels and loses
its informative power.
Data are expressed as percent for discrete variables and as
mean value 6 SD for continuous variables. Statistical signifi-
cance was accepted for all p values ,0.05.
Results
Table 1 compares the two groups with and without control
angiography at 6-month follow-up. The patients without an-
giography were older, had a higher incidence of acute myocar-
dial infarction, multivessel disease and were more often
treated with antiplatelet agents than their counterparts with
follow-up angiography. They also had a lower incidence of
smoking, unstable angina and dissections, a greater MLD
before stenting and fewer stents implanted than the group with
follow-up angiography.
Table 1. Clinical, Lesional and Procedural Characteristics in the
Group Without (265 patients, 354 lesions) and the Group With
Follow-Up Angiography (1,084 patients, 1,399 lesions)
Without
Control
Angiography
With
Control
Angiography
p
Value
Age (yr) 64.1 6 10.7 61.8 6 10.8 , 0.001
Women 21.8% 21.7% NS
Hypercholesterolemia 38.1% 41.7% NS
Systemic arterial hypertension 58.5% 61.3% NS
Smoking 34.5% 41.7% 0.013
Diabetes mellitus 19.8% 16.8% NS
Acute myocardial infarction 21.5% 15.5% 0.007
Unstable angina pectoris 25.7% 33.8% 0.004
Multivessel disease 82.2% 77.1% 0.04
Previous PTCA 15.0% 18.1% NS
Antiplatelet therapy post-
stenting
77.4% 68.5% 0.001
Recent occlusions 8.2% 6.5% NS
Chronic occlusions 3.7% 5.1% NS
Dissections 28.8% 42.5% , 0.001
Number of stents 2.23 6 1.38 2.49 6 1.48 0.003
LAD lesions 39.3% 43.2% NS
RD before stenting (mm) 3.11 6 0.58 3.10 6 0.53 NS
MLD before stenting (mm) 0.82 6 0.55 0.74 6 0.49 0.003
Balloon/vessel ratio 1.06 6 0.13 1.07 6 0.14 NS
Maximal balloon pressure
(atm)
13.6 6 2.8 13.9 6 2.9 NS
MLD after stenting (mm) 2.99 6 0.55 2.99 6 0.48 NS
Data are presented as mean value 6 SD or percent. LAD 5 left anterior
descending coronary artery; MLD 5 minimal lumen diameter; PTCA 5
percutaneous transluminal coronary angioplasty; RD 5 reference diameter.
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Univariate analysis. Several analyzed factors were associ
ated with differences with respect to the outcome variables of
this study. Thus, the risk for restenosis was higher for lesions in
older patients, patients with diabetes or previous PTCA and
lesions with chronic occlusions or multiple stents, lesions
located in the LAD and lesions with a smaller RD and MLD
before stenting and with a smaller MLD after stenting (Fig. 1,
left). In contrast, acute infarct-related lesions and, even more
surprisingly, lesions of smokers were associated with a lower
risk for restenosis. We sought specifically the influence on
restenosis of the location of the stent in saphenous vein grafts.
In the relatively small number of lesions located in vein grafts
in the present study (only 3.4% of the total number of lesions),
the restenosis rate of 27.1% did not differ significantly from
that of 26.3% encountered in native vessels (p 5 0.9). Late
lumen loss (Table 2) was significantly greater for lesions in
patients with diabetes and previous PTCA, for lesions with
multiple stents, a smaller MLD before stenting, bigger balloon/
vessel ratio and higher dilation pressure. A lesser late lumen
loss was observed only in lesions with a smaller final MLD. The
risk for TLR (Fig. 2, left) was associated with fewer factors, in
one direction only. A higher risk for TLR was observed for
lesions in older and diabetic patients, for lesions with multiple
stents and those with smaller vessel size and an MLD ,3 mm
after stenting.
Multivariate analysis. The predictive model for binary
restenosis demonstrated an overall accuracy of 74.2%. It
identified six independent factors: multiple stents, diabetes
mellitus, post-stenting MLD ,3 mm, previous PTCA, chronic
occlusions and LAD location of the lesion (Fig. 1, right). All
these factors represent an increased risk for restenosis, with an
OR ranging from 1.31 for LAD lesions to 1.86 for the presence
of diabetes mellitus. The presence of chronic occlusions was no
longer a significant factor in either univariate or multivariate
analysis when lesions that had become occluded at follow-up
angiography were omitted from the analysis. A separate anal-
ysis was performed to check whether the unexpected finding of
a higher risk for restenosis in nonsmokers by univariate
analysis was due to an interrelation with the independent risk
factors identified by the logistic regression model. As com-
pared with smokers, nonsmokers were more frequently dia-
betic (20.0% vs. 12.3%, p , 0.001) and more frequently
received multiple stents (34.6% vs. 29.5%, p 5 0.04). Both
diabetes and multiple stents had been identified as the
strongest predictive factors for restenosis in the multivariate
model.
Multiple stents, diabetes mellitus, LAD location and more
severe original stenosis as reflected by a smaller MLD before
stenting were independent correlates of a greater lumen loss at
follow-up, whereas the presence of dissections before stenting
presented an inverse relation with lumen loss (Table 2).
However, the strongest predictor of late lumen loss was the
final MLD after stenting (t value for its regression coefficient at
least twice that of other factors). Its predominant influence in
the model may explain the seemingly paradoxic finding of an
inverse correlation between RD and late lumen loss. It simply
means, for example, that achievement of a 3.00-mm final MLD
will be associated with a greater lumen loss in a 2.75-mm vessel
than in a 3.25-mm vessel, provided that the other factors
remain constant. If we remove final MLD from the model, the
relation between RD and lumen loss returns to positive, as
expected.
Using the same models we calculated the predicted proba-
bilities of binary restenosis (by means of logistic regression)
and the predicted values for late lumen loss (by means of
multiple linear regression) for all lesions, including those
without follow-up angiography. Interestingly, despite some
differences in baseline characteristics, lesions without
Figure 1. Graphic presentation of the
results of the univariate and multivar-
iate analysis of the potential risk fac-
tors for binary restenosis at follow-up
(diameter stenosis $50%). Relative
risk (left) and OR (right) with their
95% confidence intervals are dis-
played for the clinical, lesional and
procedural variables analyzed.
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follow-up angiography had only a slightly lower chance of
restenosis (25.1% vs. 26.3%, p 5 0.042) and a nonsignificant
trend for a lower lumen loss (1.06 6 0.24 vs. 1.08 6 0.24 mm,
p 5 NS) than did lesions with follow-up angiography.
Fewer variables were retained in the final logistic model for
TLR, which showed an overall accuracy of 82%. Post-stenting
MLD, multiple stents and diabetes mellitus, the strongest
predictors of the previous analyses, were the sole independent
risk factors for reintervention (Fig. 2, right panel), with ORs as
high as 2.05 for a final MLD ,3 mm.
All of these mentioned analyses were repeated on a per
patient basis. This analysis included 1,084 patients enrolled in
this study. In patients with multilesion intervention only the
first dilated lesion was used for analysis. The three main
Table 2. Analysis of the Influence of Clinical, Lesional and Procedural Factors on the Degree of Late Lumen Loss After Stenting of 1,399
Lesions in 1,084 Patients
Late Lumen Loss (mm)
Univariate
Analysis
p Value
Multiple Linear Regression
Factor
Present
Factor
Absent
Regression Coefficient
(95% CI)
p
Value
Age .62 yr* 1.09 6 0.77 1.07 6 0.74 NS . . . . . .
Women 1.13 6 0.78 1.06 6 0.75 NS . . . . . .
Hypercholesterolemia 1.07 6 0.76 1.08 6 0.76 NS . . . . . .
Systemic arterial hypertension 1.09 6 0.76 1.06 6 0.75 NS . . . . . .
Smoking 1.04 6 0.77 1.11 6 0.75 NS . . . . . .
Diabetes mellitus 1.27 6 0.81 1.04 6 0.74 , 0.001 0.23 (0.13–0.33) , 0.001
Acute myocardial infarction 1.09 6 0.75 1.08 6 0.76 NS . . . . . .
Unstable angina pectoris 1.10 6 0.78 1.07 6 0.74 NS . . . . . .
Multivessel disease 1.07 6 0.77 1.12 6 0.72 NS . . . . . .
Previous PTCA 1.17 6 0.80 1.06 6 0.74 0.047 . . . . . .
Antiplatelet therapy after stenting 1.09 6 0.74 1.06 6 0.80 NS . . . . . .
Recent occlusions 1.12 6 0.75 1.08 6 0.76 NS . . . . . .
Chronic occlusions 1.23 6 0.84 1.07 6 0.75 NS . . . . . .
Dissections 1.08 6 0.76 1.08 6 0.75 NS 20.09 (20.17–0.01) 0.028
Multiple stenting 1.26 6 0.80 0.99 6 0.72 , 0.001 0.22 (0.14–0.30) , 0.001
LAD lesions 1.12 6 0.73 1.05 6 0.77 NS 0.13 (0.05–0.21) 0.001
RD before stenting ,3.08 mm* 1.09 6 0.70 1.07 6 0.81 NS 20.28 (20.38–0.18) , 0.001
MLD before stenting ,0.7 mm* 1.13 6 0.77 1.04 6 0.74 0.028 20.13 (20.21–0.05) 0.001
Balloon/vessel ratio .1.05* 1.18 6 0.75 0.98 6 0.75 , 0.001 . . . . . .
Maximal balloon pressure .14 atm* 1.13 6 0.76 1.02 6 0.75 0.008 . . . . . .
MLD after stenting ,3 mm* 0.97 6 0.69 1.19 6 0.80 , 0.001 0.53 (0.42–0.64) ,0.001
*Entered as continuous variables in multiple linear regression analysis. Unless otherwise indicated, data are presented as mean value 6 SD. CI 5 confidence
interval; . . . 5 nonsignificant factors; other abbreviations as in Table 1.
Figure 2. Graphic presentation of
the results of the univariate and
multivariate analysis of the poten-
tial risk factors for TLR during
follow-up. Relative risk (left) and
OR (right) with their 95% confi-
dence intervals are displayed for the
clinical, lesional and procedural
variables analyzed.
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independent factors by lesion-based analysis, namely post-
stenting MLD, multiple stents and diabetes had the same
predictive power in all three multivariate models constructed
on a per patient basis. Whereas these three factors were the
only independent factors for both binary restenosis and TLR
models, the multiple linear regression model for late lumen
loss also identified reference and MLD before stenting and
lesion location in the LAD as additional independent factors,
identical to the per lesion analysis.
The results of the CART analysis allow a very descriptive
illustration of the risk of restenosis (Fig. 3) and TLR (Fig. 4).
A lesion with a single stent and an MLD $3 mm at the end of
the procedure in a nondiabetic patient has a risk for restenosis
as low as 16%. On the other extreme, a lesion in the LAD with
multiple stents in a diabetic patient has a risk for restenosis as
high as 59.4% (Fig. 3). Similar trends are shown in the tree
model for TLR as well (Fig. 4). The lowest risk for reinterven-
tion of only 9.8% can be calculated for a lesion with a good
final result (MLD $3 mm) after placement of a single stent.
The worst outcome with a 43% risk of reintervention can be
expected for a lesion in a diabetic patient with a final MLD
,3 mm after placement of multiple stents.
Figure 3. Classification and regression tree
(CART) model showing the variables that
most strongly influence the likelihood of
binary restenosis (diameter stenosis $50%)
at follow-up. The solid area of the pie
represents the percent of the lesions with
restenosis, and the open area of the pie
indicates the size of the subgroup relative to
the total group. MLDPost 5 minimal lumen
diameter immediately after stenting.
Figure 4. Classification and regression tree model
showing the variables that most strongly influence
the likelihood of TLR during follow-up. The solid
area of the pie represents the percent of the
lesions that needed reintervention, and the open
area of the pie indicates the size of the subgroup
relative to the total group. MLDPost 5 minimal
lumen diameter immediately after stenting.
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Multiple stents, final MLD ,3 mm and diabetes mellitus,
the strongest predictors of a worse outcome as demonstrated
by the logistic models for restenosis and TLR, were used for
further analysis. Rates of angiographic restenosis and of TLR
were calculated separately for the groups presenting with no,
one, two or all three factors. There was a clear increase in the
incidence of restenosis and reinterventions parallel to the
number of risk factors present (Fig. 5). Lesions without any of
these factors had a restenosis rate of 16% and a TLR rate of
only 9%, whereas the combined presence of all these factors
increased this risk to 54.0% and 43%, respectively.
Discussion
The major finding of this study is that three factors—
diabetes, multiple stents and final result after stenting—are the
strongest independent predictors of restenosis in all three
multivariate models, that is for binary restenosis, lumen loss
and TLR. They explain most of the differences in the outcome
at 6 months. The presence of diabetes mellitus increased the
risk for restenosis and TLR by a factor of 1.86 and 1.45,
respectively. This observation is in keeping with previous
studies of stenting (16,17) and PTCA (12,18,19). This higher
risk may be due to increased blood viscosity with resulting
higher shear rates (20) and enhanced smooth muscle cell
proliferation, abnormalities that are common in diabetic pa-
tients (21). The placement of multiple stents almost doubled
the risk for restenosis and TLR, which confirms reports from
previous studies (22,23). The increased risk may be due to a
larger surface area covered by stent material, but also to a
greater length of the primary lesion or of the incurred dissec-
tion, or both. Data on lesion length are missing in this study,
but in a smaller group of patients for whom this measurement
was available, we (24) found that lesion length rather than the
number of stents implanted was a significant correlate of
lumen loss at 6-month angiographic follow-up. Stent place-
ment procedure with a final MLD ,3 mm increased the
likelihood of restenosis by 50% and doubled the likelihood of
TLR. These data are in line with previous reports on stenting
(17,22,25) and PTCA (12,26–28) and further support the
prevailing paradigm in interventional cardiology, “bigger is
better” (29). Our finding of a positive correlation between the
final MLD after stenting and the amount of lumen loss is in
accord with previous clinical (24,28) and experimental studies
(30) analyzing the relation between immediate gain and late
lumen loss. It does not contradict the inverse relation between
final MLD and restenosis, as discussed earlier. This simply
signifies that hyperplasia is greater but its impact diminishes as
the final result improves.
CART analysis illustrates well the negative impact of the
combined presence of diabetes mellitus, multiple stents and
smaller final result on the risk of restenosis and reintervention
after stenting. With the exception of diabetes, these predictive
factors are available only at the end of the procedure, thus
discouraging any attempt to predict outcome from baseline
characteristics alone. However, this finding helps to design a
special procedural strategy for patients with diabetes mellitus
before stent deployment. In these patients, the best possible
final result should be achieved with the minimal number of
stents.
Our study identified several other factors with a less rele-
vant influence on restenosis. The location of the lesion in the
LAD, a chronically occluded lesion and previous PTCA aug-
mented the risk of restenosis, as described by previous studies
(12,13,17,31,32). Moreover, smaller MLDs and RDs before the
procedure were associated with more late lumen loss. Rensing
et al. (18) found a similar relation between MLD before PTCA
and late lumen loss but only a nonsignificant trend for the
association of RD with late lumen loss. The presence of
dissections before stenting appeared to play a slight protective
role against lumen loss, as previously noted for PTCA (12).
This study illustrates the low accuracy of an analysis based
solely on univariate analysis. In addition, some factors that are
not significant in univariate analysis are significant only in a
multivariate analysis. Thus, confining the entry in the multi-
variate model to only those variables significant in univariate
analysis may yield imprecise results.
Several important points strengthen the validity of the
results of this study. 1) The study group was not confined to
certain patients with specific clinical and lesion-related char-
acteristics; rather, it comprised patients with a broad spectrum
of coronary artery disease, including acute ischemic syn-
dromes. 2) During the study period the stent implantation
protocol underwent substantial changes (use of higher balloon
pressure [33] and antithrombotic therapy after stenting [5]),
allowing analysis of their impact on restenosis. The type of
post-stenting antithrombotic therapy—anticoagulant or anti-
platelet agents—had no significant effect on restenosis. Our
results on the role of balloon pressure on restenosis are more
difficult to interpret. We found no significant effect of this
procedural variable, in contrast to our expectation that a
higher balloon pressure would lower the risk of restenosis
Figure 5. Bar graph showing the increasing restenosis (gray bars) and
rate of TLR (solid bars) as the number of the strongest risk factors
present (diabetes, multiple stents and MLD immediately after stenting
,3 mm) increased. The lines above the bars represent the upper 95%
confidence interval limit.
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through a better final post-stenting result. The use of higher
balloon pressure in this study was generally dictated by the
modifications in stenting protocol adopted in recent years.
However, we cannot exclude that adverse lesion characteristics
such as eccentricity and calcifications may have played a role in
this choice, canceling the potential of high balloon pressure to
reduce the risk of restenosis. Because these lesion character-
istics were not available for analysis in this study, a controlled
study is needed to clarify definitively the influence of balloon
pressure on restenosis. 3) We used polyvalent tools for assess-
ing restenosis, because of the dissociation between clinical and
angiographic findings. We maintained the angiographic esti-
mates as part of our restenosis analysis, because restenosis
cannot be predicted from clinical variables only (12), and we
added the TLR index in an attempt to mitigate justified
concerns about pure “coronary luminology” (34).
Limitations of the study. The selection of variables exam-
ined was based on the experience at the time the study was
designed. Although additional variables might be included in
an analysis based on today’s knowledge, we wanted to confine
our study to those variables with complete and prospectively
recorded data. The only variable entered into the model
retrospectively was the type of antithrombotic therapy, because
such information has important clinical implications and is
readily and unequivocally available. The absence in the anal-
ysis of lesion characteristics such as ostial location, eccentricity
and calcifications remains a limitation of our study. Our
analysis also did not include the length of stenosis. Although
this index would not have been available for all lesions because
of the presence of recent or chronic occlusions in our study
patients, its omission deserves special attention because it
prevents us from drawing definitive conclusions about the
exact role of multiple stenting in restenosis. Future studies are
warranted to clarify whether the number of stents itself or the
original lesion length covered by stents is responsible for more
restenosis at follow-up.
A further limitation of the study is the absence of intravas-
cular ultrasound examination. This method would be able to
introduce other lesional characteristics as independent vari-
ables in the model and might have added other end points to
the study to offer better insights into the mechanisms of
restenosis. However, the advantages of this method must be
weighed against the certain added cost and risk related to this
technique (29).
Our study may be flawed by the incomplete angiographic
follow-up. A 2% to 3% overestimation of the true restenosis
rate has been predicted even for a modest 20% rate of missing
angiographic control data, as in the present study (35). In fact,
our predicted values also suggested that the restenosis rate
might have been 1.2% lower in the group without than in the
group with control angiography. This factor may have influ-
enced our final models of restenosis in a way that cannot be
anticipated.
Conclusions and clinical implications. This study demon-
strates that diabetes mellitus, multiple stents and MLD after
stenting are the three most powerful independent predictors of
restenosis after coronary stenting. Although the independent
role of multiple stents should be further addressed by future
analyses adjusting simultaneously for lesion length, our results
suggest that to avoid clinical restenosis, the interventional
cardiologist should achieve the optimal final post-stenting
lumen and be cautious about using stents in diabetic patients.
Ensuring the best possible balance between optimal final result
and number of stents implanted may outweigh the negative
effect of other predictive factors, such as diabetes, and improve
long-term outcome. However, if only a suboptimal final result
has been achieved after multiple stents have been placed in a
diabetic patient, the patient should remain under close
follow-up to prevent in due time restenosis-mediated events.
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